Prescription of nonsteroidal anti-inflammatory drugs and co-prescribed drugs for mucosal protection: Analysis of the present status based on questionnaires obtained from orthopedists in Japan

Internal Medicine

Volumn 46, Issue 13, 2007, Pages 927-931

  Tsumura, Hidetaka ^a   Tamura, Isamu ^a   Tanaka, Hiroshi ^a   Chinzei, Ryo ^a   Ishida, Tsukasa ^a   Masuda, Atsuhiro ^a   Shiomi, Hideyuki ^a   Morita, Yoshinori ^a   Yoshida, Masaru ^a   Kutsumi, Hiromu ^a   Inokuchi, Hideto ^a   Doita, Minoru ^a   Kurosaka, Masahiro ^a   Azuma, Takeshi ^a  

^a KOBE UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Gastroprotective drugs; H2 receptor antagonist; Nonsteroidal anti inflammatory drugs; Proton pump inhibitor

Indexed keywords

DICLOFENAC; ETODOLAC; GASTROINTESTINAL MUCOSA PROTECTIVE AGENT; HISTAMINE H2 RECEPTOR ANTAGONIST; LOXOPROFEN; MELOXICAM; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN DERIVATIVE; PROTON PUMP INHIBITOR; REBAMIPIDE; TEPRENONE; ZALTOPROFEN;

ARTICLE; COMPRESSION FRACTURE; DRUG CHOICE; DRUG INDICATION; GASTRODUODENAL ULCER; GASTROINTESTINAL TOXICITY; HUMAN; INTERVERTEBRAL DISK HERNIA; JAPAN; LOW BACK PAIN; MEDICAL SPECIALIST; OSTEOARTHRITIS; PRESCRIPTION; QUESTIONNAIRE; RHEUMATOID ARTHRITIS; SCIATIC NEUROPATHY; SPONDYLOSIS; SYMPTOM;

ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTI-ULCER AGENTS; ATTITUDE OF HEALTH PERSONNEL; DRUG THERAPY, COMBINATION; DRUG UTILIZATION; FEMALE; GASTRIC MUCOSA; HEALTH CARE SURVEYS; HISTAMINE H2 ANTAGONISTS; HUMANS; JAPAN; MALE; MIDDLE AGED; MUSCULOSKELETAL DISEASES; ORTHOPEDICS; PEPTIC ULCER; PHYSICIAN'S PRACTICE PATTERNS; PRIMARY PREVENTION; PROTON PUMPS; QUESTIONNAIRES;

EID: 34547903215     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.46.0003     Document Type: Article

References (20)

1. Clinard F, Bardou M, Stro C, et al. Non-steroidal anti-inflammatory and cytoprotective drug co-prescription in general practice. A general practitioner-based survey in France. Eur J Cli Pharmacol 57: 737-743, 2001.
2. Abraham NS, El-Scrag HB, Johnson ML, et al. National adherence to evidence-based guidelines for the prescription of nonsteroidal anti-inflammatory drugs. Gastroenterology 129: 1171-1178, 2005.
3. Gunnarsdottir AI, Kinnear M. Factors that influence prescribers in their selection and use of COX-2 selective inhibitors as opposed to non-selective NSAIDs. Pharm World Sci 27: 316-320, 2005.
4. Bolten WW. Scientific rationale for specific inhibition of COX2. J Rheumatol 51 (Suppl): 2-7, 1998.
5. Gabriel SE, Jaakkimainen L, Bombardier C. Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs. Ann Intern Med 115: 787-796, 1991.
6. Seager JM, Hawkey CJ. ABC of the upper gastrointestinal tract: ingestion and non-steroidal anti-inflammatory drugs. BMJ 323: 1236-1239, 2001.
7. Recommendations for the medical management of osteoarthritis of the hip and knee. (2000 update) American College of Rheumatology Subcommittee on Osteoarthritis Guidelines. Arthritis Rheum 43: 1905-1915, 2000.
8. Lanza FL and the Members of the Ad Hoc Committee on Practice Parameters of the American College Gastroenterology. A guideline for the treatment and prevention of NSAID-induced ulcers. Am J Gastroenterol. 93: 2037-2046, 1998.
9. Schnitzer TJ. Update of ACR guidelines for osteoarthritis: role of coxibs. J Pain Symptom Manage 23(suppl): S24-S30, 2002.
10. Lipsky PE. Introduction. Am J Med 110 (3A): 1S-2S, 2001.
11. Teeling M, Bennett K, Feely J. Have COX-2 inhibitors influenced the co-prescription of anti-ulcer drugs with NSAIDs? Br J Clin Pharmacol 57: 337-343, 2004.
12. Larkai EN, Smith JL, Lidsky MD, Graham DY. Gastroduodenal mucosa and dyspeptic symptoms in arthritic patients during chronic nonsteroidal anti-inflammatory drug use. Am J Gastroenterol 82: 1153-1158, 1987.
13. Bellary SV, Isaacs PET, Lee FI. Upper gastrointestinal lesions in elderly patients presenting for endoscopy; relevance of NSAID usage. Am J Gastroenterol 86: 961-964, 1991.
14. Fries JF, Williams CA, Bloch DA, Michel BA. Nonsteroidal anti-inflammatory drug-associated gastropathy: Incidence and risk factor models. Am J Med 91: 213-222, 1991.
15. Lanas A, Serrano P, Bajador E, Esteva F, Benito R, Sainz R. Evidence of aspirin use in both upper and lower gastrointestinal perforation. Gastroenterology 112: 683-689, 1997.
16. Murata H, Yabe Y, Tsuji S, et al. Gastroprotective agent rebarnipide induces cyclooxygenase-2 (COX-2) in gastric epithelial cells. Dig Dis Sci 50: S70-75, 2005.
17. Gislason GH, Jacobsen S, Rasmussen JN, et al. Risk of death or reinfarction associated with the use of selective cyclooxygenase-2 inhibitors and nonselective nonsteroidal anti-inflammatory drugs after acute myocardial infarction. Circulation 113: 2906-2913, 2006.
18. Solomon DH, Avorn J, Sturmer T, et al. Cardiovascular outcomes in new users of coxibs and nonsteroidal antiinflammatory drugs: high risk subgroups and time course of risk. Arthritis Rheum 54: 1378-1389, 2006.
19. Solomon SD. Cyclooxygenase-2 inhibitors and cardiovascular risk. Curr Opin Cardiol 21: 613-617, 2006.
20. Kagakuteki konkyo ni motozuku ikaiyou shinnryou gaidolain no sakutei ni kannsuru kennkyuhann. NSAID kaiyou yobou. in EBM ni motozuku ikaiyou shinnryou gaidolain. Jihou 95-98, 2003 (in Japanese).